Skip to main content
Premium Trial:

Request an Annual Quote

Invitae, Nanopharmacia Partner on Genetic Cancer Testing in Mexico, Costa Rica, Panama

NEW YORK (GenomeWeb) – Invitae and Nanopharmacia today announced an exclusive partnership to provide access to Invitae's genetic tests for hereditary cancers in Mexico.

The deal also will make Invitae's tests available on a non-exclusive basis in Costa Rica and Panama. Financial and other terms were not disclosed.

Nanopharmacia, a provider of cancer molecular tests in Mexico and Latin America, will make Invitae's tests available to onco-geneticists and medical and surgical oncologists. Invitae offers single-gene BRCA1/2 testing, including full gene sequencing and deletion/duplication analysis, as well as a six-gene, high-risk hereditary breast cancer panel.

The San Francisco-based firm also offers an 18-gene women's hereditary cancer panel covering hereditary breast, ovarian, and endometrial cancer; a 29-gene hereditary cancer syndrome panel; a 17-gene hereditary pancreatic cancer panel; and other hereditary panels covering cancers including Lynch syndrome and colon cancers.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.